Merck to buy Hengrui Pharma's drug for up to $1.8B

Merck to buy Hengrui Pharma's drug for up to $1.8B

Merck & Co. Inc. said on Tuesday that it entered into an exclusive license agreement with Jiangsu Hengrui Pharmaceuticals Co. Ltd. for a cardiovascular disease drug HRS-5346, currently in a phase ...

Merck & Co. will pay up to $2 billion for the rights of the experimental drug for the heart of Jiangsu Hengrui Pharmaceuticals Co, the second recent incursion of the US pharmaceutical company into China for a novel drug. According to the agreement, Merck will pay $200 million in advance to develop and market the Hengrui Pharma pill, currently in the intermediate phase of human clinical trials, according to a statement issued on Tuesday. Merck ha…

MSD enters agreement with Hengrui Pharma for Lp(a) inhibitor

MSD has entered an exclusive licence agreement with Hengrui Pharma for the oral small molecule Lp(a) inhibitor, HRS-5346.

Merck, Hengrui Launch Up-to-$2B+ Cardiometabolic Collaboration

Merck & Co. has agreed to license the oral small molecule Lipoprotein(a) [Lp(a)] inhibitor HRS-5346 from Jiangsu Hengrui Pharmaceuticals, through a licensing agreement that could generate up to $2 billion plus for the Chinese drug developer. Hengrui Pharma has granted Merck exclusive rights to develop, manufacture, and commercialize HRS-5346 worldwide, except in Greater China where Hengrui will retain rights. At China’s Peking University Third H…

Merck Makes Bold $2B Bet on Chinese Cardio Drug - USA Herald

Merck & Co. Inc. is making a high-stakes move in the cardiovascular drug market, announcing on Tuesday an exclusive licensing deal with Jiangsu Hengrui Pharmaceuticals Co. Ltd. The agreement, which sees Merck shelling out up to $2 billion, positions the company at the forefront of tackling a major global heart disease risk. Big Money, Big erck seals a $2B deal to acquire global rights to a Chinese cardio drug, HRS-5346, targeting Lp(a).

Merck Partners With Hengrui Pharma In $1.77 Billion Deal For Cardiovascular Treatment

Merck & Co Inc (NYSE:MRK) and Jiangsu Hengrui Pharmaceuticals Co., Ltd on Tuesday entered into an exclusive license agreement for HRS-5346, an investigational oral small molecule Lipoprotein(a), or Lp(a), inhibitor currently being evaluated in a Phase 2 clinical trial in China. Lipoprotein (a), or…